A patient on Vyvanse (lisdexamfetamine) is experiencing irritability, difficulty concentrating, and insomnia; what medication should I prescribe?

First, Reassess the Vyvanse Regimen Before Adding New Medications

Before prescribing additional medications, you need to determine whether these symptoms represent Vyvanse side effects, inadequate ADHD control, or both—this fundamentally changes your management approach.

The symptoms described—irritability, poor concentration, and insomnia—create a clinical dilemma because they could represent either:

1. Adverse effects from Vyvanse (irritability and insomnia are common, occurring in >5% of patients) 1
2. Inadequate ADHD symptom control (poor concentration suggests underdosing)
3. Timing issues (late-day rebound or wearing off effects)

Immediate Assessment Steps

Evaluate the temporal pattern of symptoms:

• If irritability and concentration problems occur in late afternoon/evening when Vyvanse wears off, this suggests rebound phenomenon requiring dose adjustment or timing modification 1
• If insomnia occurs despite good daytime symptom control, this is a direct stimulant side effect 1
• If concentration problems persist throughout the day, this suggests inadequate dosing 2

Check current dosing parameters:

• Vyvanse can be titrated from 30-70 mg daily in 10-20 mg weekly increments 1
• The medication provides approximately 12-hour coverage 3
• Administration timing matters—ensure morning dosing on empty stomach 1

Management Algorithm

If Symptoms Suggest Inadequate ADHD Control (Poor Concentration Predominates):

Optimize Vyvanse first by increasing the dose in 10-20 mg increments weekly up to 70 mg maximum, as inadequate dosing is the most common cause of persistent ADHD symptoms 2, 1. If concentration problems persist despite optimal Vyvanse dosing (50-70 mg), consider switching to a different stimulant formulation rather than adding medications 2.

If Symptoms Suggest Stimulant Side Effects (Irritability and Insomnia Predominate):

For insomnia management, the evidence-based approach follows this sequence 4, 5:

1. First-line: Short-intermediate acting benzodiazepine receptor agonists (BzRAs) such as:

   • Zolpidem 10 mg (5 mg in elderly) for sleep onset and maintenance 5
   • Eszopiclone 2-3 mg (1 mg in elderly) for sleep onset and maintenance 5
   • Zaleplon 10 mg (5 mg in elderly) for sleep onset only 5
   • Temazepam 15-30 mg (7.5 mg in elderly) 4

2. Alternative first-line: Ramelteon 8 mg for sleep onset, particularly if substance abuse concerns exist 5

3. Second-line if BzRAs fail: Sedating antidepressants at low doses 4:

   • Trazodone 50 mg (though the 2017 AASM guideline suggests NOT using it due to insufficient evidence) 5
   • Doxepin 3-6 mg for sleep maintenance 5
   • Mirtazapine (causes weight gain, use cautiously) 4

Critical caveat: The 2017 AASM guideline 5 specifically recommends AGAINST trazodone despite its widespread use, citing insufficient evidence. However, the 2008 guidelines 4 list it as an option. Given this contradiction and prioritizing the most recent high-quality evidence, I recommend starting with a BzRA (zolpidem or eszopiclone) rather than trazodone.

For irritability without clear mood disorder, address this by:

• Adjusting Vyvanse timing (earlier morning administration)
• Reducing Vyvanse dose if therapeutic benefit maintained
• Ensuring adequate sleep (treating insomnia often resolves irritability)

If Both Problems Coexist:

Optimize Vyvanse timing and dose first, then add a short-acting BzRA for insomnia 4. The combination of stimulant plus hypnotic is explicitly discussed in guidelines as acceptable practice 4.

What NOT to Prescribe

Avoid these options based on guideline recommendations:

• OTC antihistamines (diphenhydramine)—insufficient efficacy data 4, 5
• Melatonin—insufficient evidence 5
• Herbal supplements (valerian)—not recommended 5
• Barbiturates or chloral hydrate—explicitly not recommended 4
• Tiagabine—AASM recommends against use 5
• Atypical antipsychotics (quetiapine, olanzapine) unless comorbid psychiatric conditions exist—risk outweighs benefit 4

Essential Monitoring

If you prescribe a hypnotic, follow these requirements 4:

• Follow-up every few weeks initially
• Assess effectiveness and side effects
• Monitor for dosage escalation
• Educate about rebound insomnia risk
• Attempt to use lowest effective dose
• Consider intermittent dosing (3 nights/week) rather than nightly 4

Combine with behavioral interventions whenever possible, as cognitive behavioral therapy for insomnia (CBT-I) enhances medication effectiveness and facilitates eventual discontinuation 4, 6.

Common Pitfalls to Avoid

1. Don't reflexively add medications without optimizing Vyvanse first—many patients need dose adjustment, not additional drugs
2. Don't use trazodone as first-line despite its popularity—the most recent AASM guideline recommends against it 5
3. Don't prescribe long-acting benzodiazepines (flurazepam)—risk of daytime sedation 4
4. Don't ignore the possibility of stimulant-induced insomnia—sometimes the solution is reducing or retiming Vyvanse, not adding more medications
5. Don't forget to screen for emerging mood disorders—irritability can herald depression or bipolar disorder, which changes management entirely 1